BridgeBio Pharma (BBIO) Expected to Post Quarterly Earnings on Thursday

BridgeBio Pharma (NASDAQ:BBIO) will likely be posting its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.5423) per share and revenue of $293.47 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The company had revenue of $243.68 million for the quarter, compared to analysts’ expectations of $220.91 million. BridgeBio Pharma’s revenue was up 120.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.95) EPS. On average, analysts expect BridgeBio Pharma to post ($2.64) EPS for the current fiscal year and ($0.72) EPS for the next fiscal year.

BridgeBio Pharma Price Performance

Shares of BBIO opened at $69.37 on Wednesday. BridgeBio Pharma has a 1 year low of $60.22 and a 1 year high of $93.42. The company’s fifty day moving average is $70.94 and its two-hundred day moving average is $72.90.

Insiders Place Their Bets

In related news, CEO Neil Kumar sold 34,980 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $82.53, for a total transaction of $2,886,899.40. Following the transaction, the chief executive officer owned 243,327 shares of the company’s stock, valued at $20,081,777.31. This represents a 12.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $80.06, for a total value of $160,120.00. Following the completion of the transaction, the chief accounting officer owned 127,401 shares of the company’s stock, valued at $10,199,724.06. The trade was a 1.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 56,980 shares of company stock worth $4,578,119 in the last ninety days. 14.23% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

BBIO has been the subject of several recent analyst reports. Mizuho raised their target price on shares of BridgeBio Pharma from $96.00 to $110.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 1st. JPMorgan Chase & Co. boosted their price target on shares of BridgeBio Pharma from $100.00 to $111.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Piper Sandler increased their price target on shares of BridgeBio Pharma from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, October 19th. Citigroup cut their price target on shares of BridgeBio Pharma from $94.00 to $91.00 and set a “neutral” rating for the company in a report on Monday, October 19th. Finally, HC Wainwright restated a “buy” rating on shares of BridgeBio Pharma in a research report on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $104.40.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.